Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 01244 3D MEDICINES-B > Detailed Quotes

01244 3D MEDICINES-B

Watchlist
70.200
-2.500-3.44%
Closed  02/08 16:08 CCT
High
76.000
Open
71.700
Turnover
27.63M
Low
68.600
Pre Close
72.700
Volume
388.50K
Market Cap
17.98B
P/E(TTM)
Loss
52wk High
76.150
Shares
256.06M
P/E(Static)
Loss
52wk Low
27.700
Float Cap
17.98B
Bid/Ask %
50.00%
Historical High
76.150
Shs Float
256.06M
Volume Ratio
1.04
Historical Low
27.700
Dividend TTM
--
Div Yield TTM
--
P/B
-6.18
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.15%
Amplitude
10.18%
Avg Price
71.125
Lot Size
500
Float Cap
17.98B
Bid/Ask %
50.00%
Historical High
76.150
Shs Float
256.06M
Volume Ratio
1.04
Historical Low
27.700
Dividend TTM
--
P/B
-6.18
Dividend LFY
--
Turnover Ratio
0.15%
Amplitude
10.18%
Avg Price
71.125
Lot Size
500
Price Forecast

News

Comment

No More
Company Overview More
3D Medication Inc. (www.3d-medicines.com) is a pharmaceutical company focusing on the field of cancer treatment that has entered the commercialization stage. Adhering to the vision of “helping cancer patients live longer and better”, combined with the future trend of chronic cancer treatment, it develops next-generation oncology drugs for cancer patients around the world. The company's product line includes 12 innovative drug candidates with clinical value and differentiated or global leadership. Of these, 8 have entered clinical development or commercialization, including the world's first new PD-L1 monomonial antibody drug, which has been conditionally approved by the China Drug Administration to be marketed in China; the introduction of the first-in-class polypeptide tumor vaccine 3D189 and the Gas6/AXL inhibitor 3D229 has been approved by the FDA for global phase III MRCT clinical research; the self-developed multi-target kinase inhibitor 3D011 has also entered clinical trials In the development phase, the other 4 products targeting FGFR123\ EP4\ COX2\ CD47 respectively have also entered the clinical stage at home and abroad. Preclinical varieties also include the internationally leading dual antibody CD3xPD-L1. The company currently has an international team of more than 250 people in the development, production and commercialization of new drugs to explore better treatments for cancer patients around the world.
CEO: Zhaolong Gong
Market: Hong Kong motherboard
Listing Date: 12/15/2022
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist